{"protocolSection": {"identificationModule": {"nctId": "NCT02761252", "orgStudyIdInfo": {"id": "MEIN/15/Bil-ARC/001"}, "secondaryIdInfos": [{"id": "2015-004806-40", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Menarini International Operations Luxembourg SA", "class": "INDUSTRY"}, "briefTitle": "Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma", "officialTitle": "Bilastine and Montelukast in Patients With Seasonal Allergic Rhinoconjunctivitis and Asthma: Efficacy of Concomitant Administration - the SKY Study", "acronym": "SKY"}, "statusModule": {"statusVerifiedDate": "2019-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-04-13", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-11-24", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-11-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-04-28", "studyFirstSubmitQcDate": "2016-05-02", "studyFirstPostDateStruct": {"date": "2016-05-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-04-13", "resultsFirstSubmitQcDate": "2019-04-24", "resultsFirstPostDateStruct": {"date": "2019-07-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-04-24", "lastUpdatePostDateStruct": {"date": "2019-07-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Menarini International Operations Luxembourg SA", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare concomitant administration of Montelukast and Bilastine to Montelukast and Bilastine monotherapies in patients with SARC and asthma", "detailedDescription": "The present study (SKY) was designed to show if once daily oral combination therapy with Montelukast 10 mg and Bilastine 20 mg is superior to monotherapy with Bilastine 20 mg in patients with Seasonal Allergic RhinoConjunctivitis (SARC) and comorbid mild to moderate asthma on total symptom scores (TSS) and if the combination therapy reflects an improvement in quality of life as assessed via the Asthma Quality of Life Questionnaire (AQLQ) over a longer time period when compared to monotherapies with Montelukast 10 mg and Bilastine 20 mg. Mild to moderate asthma was defined according to the criteria of the Global Initiative for Asthma, i.e., GINA criteria 2 and 3 (GINA, 2012). The study population included patients inadequately controlled on inhaled corticosteroids and in whom \"as-needed\" short acting beta-agonists provided inadequate clinical control."}, "conditionsModule": {"conditions": ["Seasonal Allergic Rhinoconjunctivitis", "Asthma"], "keywords": ["Bilastine", "Montelukast", "total symptom score", "AQLQ"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "The study was a randomised (1:1:1), double-blind, double-dummy, interventional, active-controlled, parallel groups (three groups), multi-centre, multi-national, superiority clinical trial. The study plan included a 7-day (\u00b1 4) run-in period to ensure wash-out from previous forbidden treatments and to perform the tests required to ensure appropriate patient enrolment into the study. The active treatment period was 12 weeks (85 days) with a follow-up visit (phone call) at 28 days (\u00b1 4) after the End of Treatment.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "maskingDescription": "The principal investigator and study staff, subjects and monitors remained blinded to the treatment until study closure in this double-blind, double-dummy study. The identity of the study drug was revealed only if the subject experienced a medical emergency the management of which would be improved by the knowledge of the blinded treatment assignment.\n\nAs the combination therapy of Bilastine + Montelukast consisted of two tablets in contrast to monotherapy with either Bilastine or Montelukast, the double-dummy technique was applied with matching placebo for each Investigation Medicinal Product (IMP) (monotherapy with Bilastine or Montelukast) to ensure the maintenance of double-blind conditions. Therefore, each patient took 2 tablets with each dose administered.\n\nAs by randomisation list, each Patient Kit consisted of two IMP treatments (either active + placebo or active + active) in separate blisters packed in two different boxes.", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 454, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Bilastine+montelukast", "type": "EXPERIMENTAL", "description": "Bilastine 20 mg, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each for treatment", "interventionNames": ["Drug: Bilastine 20mg", "Drug: Montelukast 10mg"]}, {"label": "Bilastine+placebo montelukast", "type": "ACTIVE_COMPARATOR", "description": "Bilastine 20 mg, 10 blister containing 10 tablets + Placebo Montelukast, 10 blister containing 10 film coated tablets each.", "interventionNames": ["Drug: Bilastine 20mg", "Drug: Placebo Montelukast 10mg"]}, {"label": "Montelukast+placebo bilastine", "type": "ACTIVE_COMPARATOR", "description": "Placebo Bilastine, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each.", "interventionNames": ["Drug: Montelukast 10mg", "Drug: Placebo Bilastine 20mg"]}], "interventions": [{"type": "DRUG", "name": "Bilastine 20mg", "armGroupLabels": ["Bilastine+montelukast", "Bilastine+placebo montelukast"], "otherNames": ["Robilas"]}, {"type": "DRUG", "name": "Montelukast 10mg", "armGroupLabels": ["Bilastine+montelukast", "Montelukast+placebo bilastine"], "otherNames": ["Montelukast"]}, {"type": "DRUG", "name": "Placebo Bilastine 20mg", "armGroupLabels": ["Montelukast+placebo bilastine"], "otherNames": ["Placebo Bilastine"]}, {"type": "DRUG", "name": "Placebo Montelukast 10mg", "armGroupLabels": ["Bilastine+placebo montelukast"], "otherNames": ["Placebo Montelukast"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline With Montelukast+Bilastine Compared With Bilastine Monotherapy in SARC Symptoms", "description": "To demonstrate that concomitant administration of montelukast and bilastine is superior to bilastine monotherapy in SARC symptoms, as assessed by Total Symptoms Scores (TSS) after 4 weeks of treatment.\n\nTotal Symptoms Scores (TSS) assesses nasal (nasal congestion, rhinorrhea, nasal itching, sneezing) and non nasal symptoms (ocular redness, ocular itching, tearing) of rhinoconjuctivits.\n\nEach of the 7 symptoms is scored from 0 (absent) to 3 (severe) as follows:\n\n* 0 (absent) Symptom not present\n* 1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness\n* 2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep\n* 3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.\n\nTSS assessment comprises of scoring (0-3) of all 7 above mentioned symptoms. Final TSS scores is in a range from 0-21.", "timeFrame": "4 weeks of treatment (from baseline to 4 weeks of treatment)"}], "secondaryOutcomes": [{"measure": "Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in Asthma Control", "description": "To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in asthma control, as assessed by Asthma Quality of Life Questionnaire (AQLQ) after 4 weeks.\n\nThe AQLQ was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.\n\nEach of the 32 questionnaire's items will be scored on a 7-point scale (where 7 means \"not impaired at all\" and 1 means \"severely impaired\"). The overall AQLQ score is the mean of all 32 responses (https://www.qoltech.co.uk/aqlq.html).\n\nThe change in AQLQ score from baseline to 4 weeks after treatment - AQLQ score at baseline for patients with both available values has been the secondary endpoint.", "timeFrame": "After 4 weeks of treatments"}, {"measure": "Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNSS)", "description": "To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Nasal Symptom Score (DNSS) after 4 weeks of treatment.\n\nDaytime Nasal Symptom Score (DNSS) is the average of individual scores of nasal congestion, rhinorrhea, nasal itching, sneezing of rhinoconjuctivits.\n\nEach of the 4 symptoms is scored from 0 (absent) to 3 (severe) as follows:\n\n* 0 (absent) Symptom not present\n* 1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness\n* 2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep\n* 3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.\n\nDNSS assessment comprises of scoring (0-3) of all 4 above mentioned symptoms. Final DNSS scores is in a range from 0-12.", "timeFrame": "After 4 weeks of treatment (from baseline)"}, {"measure": "Change From Baseline With Montelukast + Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNNSS)", "description": "To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Non Nasal Symptom Score (DNNSS) after 4 weeks of treatment.\n\nDaytime Non Nasal Symptom Score (DNSS) is the average of individual scores of ocular redness, ocular itching and tearing of rhinoconjuctivits.\n\nEach of the 3 symptoms is scored from 0 (absent) to 3 (severe) as follows:\n\n* 0 (absent) Symptom not present\n* 1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness\n* 2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep\n* 3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.\n\nDNNSS assessment comprises of scoring (0-3) of all 3 above mentioned symptoms. Final DNNSS scores is in a range from 0-9.", "timeFrame": "After 4 weeks of treatment (from baseline)"}, {"measure": "Usage of Relief Medication for SARC", "description": "Number of days without any relief medication for SARC", "timeFrame": "From baseline to 4 weeks of treatment"}, {"measure": "Usage of Relief Medication for Asthma", "description": "Number of days without any relief medication for Asthma.", "timeFrame": "From baseline to 4 weeks of treatment"}]}, "eligibilityModule": {"eligibilityCriteria": "INCLUSION CRITERIA\n\n1. Patients aged 18 years or older;\n2. Patients with at least 2 years history of SARC prior to the study and mild to moderate asthma (GINA criteria 2 and 3) inadequately controlled on inhaled corticosteroids and in whom \"as-needed\" short acting beta-agonists provide inadequate clinical control;\n3. Forced expiratory volume at one second (FEV1) \\> 70% of the predicted normal value demonstrable at least 6 hours after last short acting \u03b2-2 agonist use or 12 hours after last long acting \u03b2-2 agonist (LABA) use;\n4. Nasal Symptoms Score (NSS) at baseline \u2265 3. Baseline NSS will be defined as the mean of the 6 last assessments of the patients' diary (3 last days before randomization);\n5. Positive results of skin prick test on at least one seasonal allergen within the last 3 years;\n6. Patients who provided a signed written informed consent form;\n7. Patients who are able and willing to complete web-based Patient's Diary;\n8. Patients who agree to maintain consistency in their surroundings throughout the study period;\n9. Women of childbearing potential (WOCBP) including peri-menopausal women who have had a menstrual period within 1 year have to have a negative pregnancy test. Results have to be available until the Visit 2 and negative for the patient to be entered in the study.\n10. WOCBP have to use an effective method of birth control throughout the study period and for 4 weeks after study completion (defined as a method which results in a failure rate of less than 1% per year) such as:\n\n    * combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)\n    * progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)\n    * intrauterine device (IUD)\n    * intrauterine hormone-releasing system (IUS)\n    * bilateral tubal occlusion\n    * vasectomised partner (provided that partner is the sole sexual partner of the trial participant and that the vasectomised partner has received medical assessment of the surgical success)\n    * sexual abstinence In each case of delayed menstrual period (over one month between menstruations) confirmation of absence of pregnancy is strongly recommended. This recommendation also applies to WOCBP with infrequent or irregular menstrual cycles.\n\nEXCLUSION CRITERIA\n\n1. Patients with hypersensitivity to any component of the study medications;\n2. Patients with non-allergic rhinoconjunctivitis (e.g. vasomotor, infectious, drug-induced);\n3. Presence of nasal polyps or any clinically important nasal anomaly;\n4. History of acute and/or chronic sinusitis within 30 days of Visit 2;\n5. History of eye surgery within 3 months of Visit 2;\n6. History of intranasal surgery within 3 months of Visit 2;\n7. Immunotherapy within 6 months prior to Visit 1;\n8. Upper respiratory infections including cold and systemic infections within 3 weeks of Visit 2;\n9. Patients with moderate to severe renal impairment and taking P-gp inhibitors (e.g. ketoconazole, erythromycin, cyclosporine, ritonavir, diltiazem) within 7 days prior to the first dose of study medication;\n10. Patients requiring daily \"controller\" medications with cromolyn-type drugs or leukotriene antagonists;\n11. Patient required daily \"controller\" medication with Inhaled corticosteroids (ICS) or LABA at medium /high dosage defined by GINA criteria;\n12. Patients with clinically important (based on principal investigator's judgment) hepatic impairment;\n13. Patients with severe concomitant disease (based on principal investigator's judgment) that could interfere with treatment response;\n14. Patients with QT syndrome;\n15. Patients with Galactose intolerance, Lapp lactase deficiency or glucose- galactose malabsorption;\n16. Pregnant or breast-feeding women;\n17. Patients with a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study (based on principal investigator's judgment);\n18. Patients who had a recent history (within previous 12 months) of drug addiction or alcohol abuse based on Principal investigator's judgment ;\n19. Patients participating in or having participated in another clinical trial within the previous three months;\n20. Patients unable to take relief medications due to contraindications or intolerance;\n21. Patients who are taking or have taken any of the following medications prior to randomisation in the study and have not complied with the specified washout period:\n\n    * Antihistaminic drugs or montelukast (7 days)\n    * Systemic or intranasal corticosteroids (4 weeks)\n    * Delayed-release corticosteroids (3 months)\n    * Ketotifen (2 weeks)\n    * Macrolides antibiotics and imidazolic antifungals (systemic)(7 days)\n    * Anticholinergics (7 days)\n    * Drugs with antihistamine properties (phenothiazine) (7 days)\n    * Intranasal and systemic decongestants (3 days)\n    * Lodoxamide (7 days)\n22. Patients who will be operating heavy machinery or need to drive motor vehicles as an essential part of their profession.\n23. Patients who are planning to travel outside the study area during the course of the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Massimo Pistolesi, Prof", "affiliation": "AOUC Azienda Ospedaliero-Universitaria Careggi", "role": "STUDY_DIRECTOR"}, {"name": "Oliviero Rossi, Prof", "affiliation": "AOUC Azienda Ospedaliero-Universitaria Careggi", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Cakovec", "country": "Croatia", "geoPoint": {"lat": 46.38444, "lon": 16.43389}}, {"city": "Rijeka", "country": "Croatia", "geoPoint": {"lat": 45.32674, "lon": 14.44239}}, {"city": "Zagreb", "country": "Croatia", "geoPoint": {"lat": 45.81444, "lon": 15.97798}}, {"city": "Brno", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"city": "Ostrava Hrabuvka", "country": "Czechia", "geoPoint": {"lat": 49.83465, "lon": 18.28204}}, {"city": "Teplice", "country": "Czechia", "geoPoint": {"lat": 50.6404, "lon": 13.82451}}, {"city": "Dreieich", "country": "Germany", "geoPoint": {"lat": 50.01997, "lon": 8.69611}}, {"city": "Heidelberg", "country": "Germany", "geoPoint": {"lat": 49.40768, "lon": 8.69079}}, {"city": "Catania", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"city": "Florence", "country": "Italy", "geoPoint": {"lat": 43.77925, "lon": 11.24626}}, {"city": "Modena", "country": "Italy", "geoPoint": {"lat": 44.64783, "lon": 10.92539}}, {"city": "Pavia", "country": "Italy", "geoPoint": {"lat": 45.19205, "lon": 9.15917}}, {"city": "Verona", "country": "Italy", "geoPoint": {"lat": 45.4299, "lon": 10.98444}}, {"city": "Riga", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"city": "Bialystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"city": "Bielsko-Biala", "country": "Poland", "geoPoint": {"lat": 49.82245, "lon": 19.04686}}, {"city": "Gdansk", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"city": "Katowice", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"city": "Krakow", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"city": "Lodz", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"city": "Lublin", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"city": "Nowy Duninow", "country": "Poland", "geoPoint": {"lat": 52.58271, "lon": 19.47996}}, {"city": "Poznan", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"city": "Rzeszow", "country": "Poland", "geoPoint": {"lat": 50.04132, "lon": 21.99901}}, {"city": "Tarnow", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"city": "Wroclaw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"city": "Brasov", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"city": "Cluj Napoca", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"city": "Ploie\u015fti", "country": "Romania", "geoPoint": {"lat": 44.95, "lon": 26.01667}}, {"city": "Bardejov", "country": "Slovakia", "geoPoint": {"lat": 49.29175, "lon": 21.27271}}, {"city": "Levice", "country": "Slovakia", "geoPoint": {"lat": 48.21563, "lon": 18.60705}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "454 patients were enrolled but 34 patients did not met inclusion/exclusion critera.", "recruitmentDetails": "The recruitment started on 13 April 2016 and termineted on 23 November 2016. 454 patients with SARC and mild to moderate asthma as comorbidity were screened.\n\n420 patients were randomised of which 388 patients completed the study.", "groups": [{"id": "FG000", "title": "Bilastine+Montelukast", "description": "Bilastine 20mg\n\nMontelukast 10mg"}, {"id": "FG001", "title": "Bilastine Monotherapy", "description": "Bilastine 20mg\n\nPlacebo Montelukast 10mg"}, {"id": "FG002", "title": "Montelukast Monotherapy", "description": "Montelukast 10mg\n\nPlacebo Bilastine 20mg"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "143"}, {"groupId": "FG001", "numSubjects": "140"}, {"groupId": "FG002", "numSubjects": "137"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "133"}, {"groupId": "FG001", "numSubjects": "132"}, {"groupId": "FG002", "numSubjects": "123"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "14"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Bilastine+Montelukast", "description": "Bilastine 20mg\n\nMontelukast 10mg"}, {"id": "BG001", "title": "Bilastine Monotherapy", "description": "Bilastine 20mg\n\nPlacebo Montelukast 10mg"}, {"id": "BG002", "title": "Montelukast Monotherapy", "description": "Montelukast 10mg\n\nPlacebo Bilastine 20mg"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "143"}, {"groupId": "BG001", "value": "140"}, {"groupId": "BG002", "value": "137"}, {"groupId": "BG003", "value": "420"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "143"}, {"groupId": "BG001", "value": "140"}, {"groupId": "BG002", "value": "137"}, {"groupId": "BG003", "value": "420"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "34.9", "spread": "11.1"}, {"groupId": "BG001", "value": "35.5", "spread": "11.0"}, {"groupId": "BG002", "value": "35.4", "spread": "10.7"}, {"groupId": "BG003", "value": "35.2", "spread": "10.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "69"}, {"groupId": "BG001", "value": "83"}, {"groupId": "BG002", "value": "73"}, {"groupId": "BG003", "value": "225"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "74"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "64"}, {"groupId": "BG003", "value": "195"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline With Montelukast+Bilastine Compared With Bilastine Monotherapy in SARC Symptoms", "description": "To demonstrate that concomitant administration of montelukast and bilastine is superior to bilastine monotherapy in SARC symptoms, as assessed by Total Symptoms Scores (TSS) after 4 weeks of treatment.\n\nTotal Symptoms Scores (TSS) assesses nasal (nasal congestion, rhinorrhea, nasal itching, sneezing) and non nasal symptoms (ocular redness, ocular itching, tearing) of rhinoconjuctivits.\n\nEach of the 7 symptoms is scored from 0 (absent) to 3 (severe) as follows:\n\n* 0 (absent) Symptom not present\n* 1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness\n* 2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep\n* 3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.\n\nTSS assessment comprises of scoring (0-3) of all 7 above mentioned symptoms. Final TSS scores is in a range from 0-21.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "score on a scale", "timeFrame": "4 weeks of treatment (from baseline to 4 weeks of treatment)", "groups": [{"id": "OG000", "title": "Bilastine+Montelukast", "description": "Bilastine 20mg+Montelukast 10mg"}, {"id": "OG001", "title": "Bilastine Monotherapy", "description": "Bilastine 20mg\n\nPlacebo Montelukast 10mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "143"}, {"groupId": "OG001", "value": "140"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.2522", "lowerLimit": "-3.8718", "upperLimit": "-2.6327"}, {"groupId": "OG001", "value": "-3.4462", "lowerLimit": "-4.0708", "upperLimit": "-2.8217"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.5721", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.194", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.8693", "ciUpperLimit": "0.4813", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.3429"}]}, {"type": "SECONDARY", "title": "Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in Asthma Control", "description": "To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in asthma control, as assessed by Asthma Quality of Life Questionnaire (AQLQ) after 4 weeks.\n\nThe AQLQ was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.\n\nEach of the 32 questionnaire's items will be scored on a 7-point scale (where 7 means \"not impaired at all\" and 1 means \"severely impaired\"). The overall AQLQ score is the mean of all 32 responses (https://www.qoltech.co.uk/aqlq.html).\n\nThe change in AQLQ score from baseline to 4 weeks after treatment - AQLQ score at baseline for patients with both available values has been the secondary endpoint.", "populationDescription": "The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.\n\nThe drop-out patient was, instead, included in a Safety Population (420 patients).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "score on a scale", "timeFrame": "After 4 weeks of treatments", "groups": [{"id": "OG000", "title": "Bilastine+Montelukast", "description": "Bilastine 20mg + Montelukast 10mg"}, {"id": "OG001", "title": "Bilastine Monotherapy", "description": "Bilastine 20mg\n\nPlacebo Montelukast 10mg"}, {"id": "OG002", "title": "Montelukast Monotherapy", "description": "Montelukast 10mg\n\nPlacebo Bilastine 20mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "143"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "136"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.6250", "lowerLimit": "0.4788", "upperLimit": "0.7712"}, {"groupId": "OG001", "value": "0.6399", "lowerLimit": "0.4929", "upperLimit": "0.7870"}, {"groupId": "OG002", "value": "0.5849", "lowerLimit": "0.4344", "upperLimit": "0.7353"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0105", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.1552", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.0379", "ciUpperLimit": "-0.2725", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.4489"}]}, {"type": "SECONDARY", "title": "Change From Baseline With Montelukast+Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNSS)", "description": "To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Nasal Symptom Score (DNSS) after 4 weeks of treatment.\n\nDaytime Nasal Symptom Score (DNSS) is the average of individual scores of nasal congestion, rhinorrhea, nasal itching, sneezing of rhinoconjuctivits.\n\nEach of the 4 symptoms is scored from 0 (absent) to 3 (severe) as follows:\n\n* 0 (absent) Symptom not present\n* 1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness\n* 2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep\n* 3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.\n\nDNSS assessment comprises of scoring (0-3) of all 4 above mentioned symptoms. Final DNSS scores is in a range from 0-12.", "populationDescription": "The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.\n\nThe drop-out patient was, instead, included in a Safety Population (420 patients).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "score on a scale", "timeFrame": "After 4 weeks of treatment (from baseline)", "groups": [{"id": "OG000", "title": "Bilastine+Montelukast", "description": "Bilastine 20mg\n\nMontelukast 10mg"}, {"id": "OG001", "title": "Bilastine Monotherapy", "description": "Bilastine 20mg\n\nPlacebo Montelukast 10mg"}, {"id": "OG002", "title": "Montelukast Monotherapy", "description": "Montelukast 10mg\n\nPlacebo Bilastine 20mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "143"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "136"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.9713", "lowerLimit": "-2.3442", "upperLimit": "-1.5984"}, {"groupId": "OG001", "value": "-2.1106", "lowerLimit": "-2.4863", "upperLimit": "-1.7349"}, {"groupId": "OG002", "value": "-1.8678", "lowerLimit": "-2.2468", "upperLimit": "-1.4888"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.4885", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.1393", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.5342", "ciUpperLimit": "0.2557", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.2009"}]}, {"type": "SECONDARY", "title": "Change From Baseline With Montelukast + Bilastine Compared With Montelukast and Bilastine Monotherapies in SARC Symptoms (DNNSS)", "description": "To evaluate the efficacy of concomitant montelukast and bilastine compared with montelukast and bilastine monotherapies in daytime symptoms of SARC, as assessed by Daytime Non Nasal Symptom Score (DNNSS) after 4 weeks of treatment.\n\nDaytime Non Nasal Symptom Score (DNSS) is the average of individual scores of ocular redness, ocular itching and tearing of rhinoconjuctivits.\n\nEach of the 3 symptoms is scored from 0 (absent) to 3 (severe) as follows:\n\n* 0 (absent) Symptom not present\n* 1 (mild) Symptom is clearly present but easily tolerated, a nuisance, minimal awareness\n* 2 (moderate) Symptom is bothersome but tolerable, does not interfere with daily activities or sleep\n* 3 (severe) Symptom is hard to tolerate and interferes with daily activities or sleep.\n\nDNNSS assessment comprises of scoring (0-3) of all 3 above mentioned symptoms. Final DNNSS scores is in a range from 0-9.", "populationDescription": "The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.\n\nThe drop-out patient was, instead, included in a Safety Population (420 patients).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "score on a scale", "timeFrame": "After 4 weeks of treatment (from baseline)", "groups": [{"id": "OG000", "title": "Bilastine+Montelukast", "description": "Bilastine 20mg + Montelukast 10mg"}, {"id": "OG001", "title": "Bilastine Monotherapy", "description": "Bilastine 20mg\n\nPlacebo Montelukast 10mg"}, {"id": "OG002", "title": "Montelukast Monotherapy", "description": "Montelukast 10mg\n\nPlacebo Bilastine 20mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "143"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "136"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2824", "lowerLimit": "-1.5667", "upperLimit": "-0.9980"}, {"groupId": "OG001", "value": "-1.3185", "lowerLimit": "-1.6051", "upperLimit": "-1.0320"}, {"groupId": "OG002", "value": "-1.1574", "lowerLimit": "-1.4462", "upperLimit": "-0.8687"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.81032", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.03615", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.3319", "ciUpperLimit": "0.2596", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1504"}]}, {"type": "SECONDARY", "title": "Usage of Relief Medication for SARC", "description": "Number of days without any relief medication for SARC", "populationDescription": "The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.\n\nThe drop-out patient was, instead, included in a Safety Population (420 patients).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Days", "timeFrame": "From baseline to 4 weeks of treatment", "groups": [{"id": "OG000", "title": "Bilastine+Montelukast", "description": "Bilastine 20mg + Montelukast 10mg"}, {"id": "OG001", "title": "Bilastine Monotherapy", "description": "Bilastine 20mg\n\nPlacebo Montelukast 10mg"}, {"id": "OG002", "title": "Montelukast Monotherapy", "description": "Montelukast 10mg\n\nPlacebo Bilastine 20mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "143"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "136"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.0057", "spread": "0.8260"}, {"groupId": "OG001", "value": "15.8416", "spread": "0.8326"}, {"groupId": "OG002", "value": "15.4179", "spread": "0.8411"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.3704", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.8359", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.9969", "ciUpperLimit": "2.6688", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.9322"}]}, {"type": "SECONDARY", "title": "Usage of Relief Medication for Asthma", "description": "Number of days without any relief medication for Asthma.", "populationDescription": "The Intention To Treat population (used for statistical analysis) was 419 patients because 1 patient in Montekukast Monotherapy arm was a drop-out.\n\nThe drop-out patient was, instead, included in a Safety Population (420 patients).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Days", "timeFrame": "From baseline to 4 weeks of treatment", "groups": [{"id": "OG000", "title": "Bilastine+Montelukast", "description": "Bilastine 20mg + Montelukast 10mg"}, {"id": "OG001", "title": "Bilastine Monotherapy", "description": "Bilastine 20mg\n\nPlacebo Montelukast 10mg"}, {"id": "OG002", "title": "Montelukast Monotherapy", "description": "Montelukast 10mg\n\nPlacebo Bilastine 20mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "143"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "136"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "53.2548", "spread": "2.0193"}, {"groupId": "OG001", "value": "52.4177", "spread": "2.0212"}, {"groupId": "OG002", "value": "50.7146", "spread": "2.0768"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.7452", "statisticalMethod": "ANOVA", "paramType": "Median Difference (Final Values)", "paramValue": "-0.837", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.8968", "ciUpperLimit": "4.2228", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.5735"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Bilastine+Montelukast", "description": "Bilastine 20 mg, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each for treatment\n\nBilastine 20mg\n\nMontelukast 10mg", "seriousNumAffected": 0, "seriousNumAtRisk": 143, "otherNumAffected": 8, "otherNumAtRisk": 143}, {"id": "EG001", "title": "Bilastine+Placebo Montelukast", "description": "Bilastine 20 mg, 10 blister containing 10 tablets + Placebo Montelukast, 10 blister containing 10 film coated tablets each.\n\nBilastine 20mg\n\nPlacebo Montelukast 10mg", "seriousNumAffected": 0, "seriousNumAtRisk": 140, "otherNumAffected": 4, "otherNumAtRisk": 140}, {"id": "EG002", "title": "Montelukast+Placebo Bilastine", "description": "Placebo Bilastine, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each.\n\nMontelukast 10mg\n\nPlacebo Bilastine 20mg", "seriousNumAffected": 1, "seriousNumAtRisk": 137, "otherNumAffected": 14, "otherNumAtRisk": 137}], "seriousEvents": [{"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}]}], "otherEvents": [{"term": "Alanine Aminotransferase Increased", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 137}]}, {"term": "Aspartate Aminotransferase Increased", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 137}]}, {"term": "Gamma-glutamytrasferase Increased", "organSystem": "Investigations", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 137}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}]}, {"term": "Sedation", "organSystem": "Nervous system disorders", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 137}]}, {"term": "Fatigue", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 137}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 137}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 137}]}, {"term": "Irritability", "organSystem": "Psychiatric disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}]}, {"term": "Gastrooesophageal Reflux Disease", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}]}, {"term": "Gingival Bleeding", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}]}, {"term": "Hypoaesthesia oral", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}]}, {"term": "Increased appetite", "organSystem": "Metabolism and nutrition disorders", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 137}]}, {"term": "Oedema Peripheral", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 143}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 137}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Medical Director", "organization": "Menarini International Operations Luxembourg SA", "email": "aconte@menarini.lu", "phone": "+352 2649761"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Czech Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000003233", "term": "Conjunctivitis, Allergic"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000003231", "term": "Conjunctivitis"}, {"id": "D000003229", "term": "Conjunctival Diseases"}, {"id": "D000005128", "term": "Eye Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M6455", "name": "Conjunctivitis", "relevance": "LOW"}, {"id": "M6457", "name": "Conjunctivitis, Allergic", "asFound": "Allergic Rhinoconjunctivitis", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M6453", "name": "Conjunctival Diseases", "relevance": "LOW"}, {"id": "M8271", "name": "Eye Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC11", "name": "Eye Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}